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Immunohistochemistry has become an impor-
tant tool in surgical pathology, especially in the
diagnosis of tumours. The demonstration of
antigens more or less specific for different
types of tumours has dramatically improved
diagnostic accuracy. As well as being diagnos-
tically important, the expression of several
antigens as demonstrated by immunohisto-
chemistry correlates with the prognosis of
some cancers. Examples are steroid receptors
in breast and gynaecological cancers,' onco-
gene products such as HER-2/neu in breast
cancer,2 apoptosis related gene products such
as bcl-2 in breast cancer,3 and cell cycle regu-
lation proteins such as p53 (unpublished
data), pRb,5 and cyclin DI in breast, and head
and neck cancer.6 7
However, the initial promising results of
studies on these markers could not always be
confirmed. This may be because of different
methodological problems. First, there may
have been selection of patients and differences
in treatment. Second, there are often differ-
ences in tissue processing from study to study,
especially with regard to the type of antibody
and the application of antigen retrieval. Third,
and possibly most important, interpretation of
staining and presentation of the results are not
standardised resulting in low intraobserver and
interobserver reproducibility. These problems
are a very important obstruction for possible
clinical applications. There is therefore a clear
need for consensus on a protocol for scoring of
immunohistochemical staining.
The aim of this article is to discuss the most
important items that should be part of a proto-
col for the scoring of immunohistochemical
staining (staining patterns, tumour area to be
assessed, sampling of fields of vision, scoring
method, decision thresholds) and to suggest
some solutions for common problems to reach
a more standardised interpretation and presen-
tation of immunohistochemical staining re-
sults. Scoring of immunocytochemical staining
will not specifically be addressed, although
many of the issues discussed will be applicable
to cytological material.
Tissue processing
There are several steps in tissue processing that
may influence staining patterns and intensity.
These include type and duration of fixation,
section thickness, antigen retrieval procedures,
type and concentrations of primary, second
(and third) step antibodies, and way of staining
development-for example, it has recently
been reported that tumour marker immuno-
staining intensity may be lost on stored paraffin
wax slides of breast cancer.8 It is beyond the
scope ofthis article to give an in depth overview
of these factors, but these variables should be
standardised as much as possible. Technically
inadequate slides (uneven staining, uneven
section thickness, heavy background) should
be discarded.
Staining patterns
To arrive at reproducible interpretation, there
must be agreement on the significance of
nuclear, diffuse cytoplasmic or membrane
staining for each specific antibody. Most
antigens either localise (functionally) in the
nucleus (such as pRb, p53, cyclin Dl, steroid
receptors), in the cytoplasm (Bax) or in the
cellular membrane (HER-2/neu). Staining pat-
terns other than the typical pattern for a given
antibody (for example, cytoplasmic rather than
nuclear staining for steroid receptors, or diffuse
cytoplasmic instead of membrane staining for
HER-2/neu) may have to be regarded as
unfunctional and ignored, although for some
antigens it will be useful to record these seem-
ingly aberrant expression patterns until their
biological role and clinical significance are bet-
ter understood.'"
Area to be assessed
Although a purely random approach may
sometimes be optimal, it will for most applica-
tions be necessary to define in which part ofthe
lesion the staining will be assessed. For
instance, invasive areas may be chosen over in
situ parts, for proliferation markers the periph-
ery of tumours is preferred. For prognostic
applications, often the most poorly differenti-
ated area of the tumour will be selected as
this yields best clinical correlations, but for
801
van Diest, van Dam, Henzen-Logmans, Berns, van der Burg, Green, et al
diagnostic applications the best differentiated
areas are usually most useful because typical
antigen patterns are best preserved. The
tumour area to be selected should be clearly
defined for each marker, and guidelines for the
(minimal) size of this area (to be marked on the
slide for future reference) must be given.
Sampling of fields ofvision
Within the marked tumour area, it will usually
neither be possible (considering the workload
involved) nor necessary to assess all available
fields of vision. Therefore, some form of
sampling will have to be applied. It is a matter
of experience" 12 that this should not be left to
the convenience of the observer as this will lead
to interobserver variation and lack of
reproducibility. Since some degree of cluster-
ing is usually present, the best way of sampling
fields of vision is usually by systematically
spreading them over the whole chosen tumour
area (fig 1). This makes sure that cells over the
whole chosen area are assessed and will lead to
the most representative sample and highest
reproducibility." 12
Assessment of positivity of
immunohistochemical staining
QUAUTATIVE ASSESSMENT
Qualitative assessment of immunohistochemi-
cal staining is widely used to judge visually
whether any positivity of staining (compared
with the background) is present in the cells
under study. This way of assessing positivity is
often the usual practice for diagnostic reasons
and is quite satisfactory for stains where the
mere presence of antigens is informative
irrespective of the degree of positivity or the
fraction of positive cells, such as for keratins
and CD31.
QUANTITATIVE ASSESSMENT
For certain antigens, especially those predictive
ofresponse to treatment or related to prognosis
such as p53, cyclin DI, steroid receptors,
Area of interest
Sop1
Field of vision
OC Positive nucleus
O Negative nucleus
cathepsin D, and multidrug resistance related
proteins, one needs to know the degree of posi-
tivity and the fraction of positive cells. A more
sophisticated scoring procedure than qualita-
tive assessment is needed. Such staining has
semiquantitatively been scored as: -(negative),
+ (positive), ++ (strongly positive), or +++
(very strongly positive). Although this ap-
proach may be very intuitive, problems arise
when there is heterogeneity in staining-for
example, it is usually not clear what to do with
heavy staining in just a small number of cells.
Some have advocated to report the staining
intensity and the percentage of positive cells.
An even more refined method is the
Histo-score,3 14 where the fractions of negative
(score 0), weakly positive (score 1), positive
(score 2), strongly positive (score 3), and very
strongly positive (score 4) cells are estimated,
the fractions are multiplied with the scores and
summed, the total being the H-score. This
method is widely applied to score steroid
receptor positivity in breast cancer. However,
in practice, the fractions are only roughly esti-
mated without counting, and assigning a score
to an individual nucleus is highly subjective.
Studies have shown that the scoring of no
staining (score 0) and very strong staining
(score 4) is quite reproducible, but that there
are many interobserver discrepancies in scores
1-3.'4 Therefore, this method is not optimal.
Alternatively, image analysis has been ap-
plied. Theoretically, image analysis allows the
assessment ofthe amount of staining per cell by
measuring absorption. However, in practice,
immunohistochemistry using diaminobenzi-
dine (DAB) as chromogen appeared to be only
stoichiometric (linear relation between the
amount of antigen and staining intensity as
measured by degree of absorption) at low levels
of intensity and not at the usual intensities used
in daily immunohistochemistry. 5 This ap-
proach has therefore lost some of its initial
popularity. Using the alkaline phosphatase
antialkaline phosphatase (APAAP) approach or
antibodies directly labelled with a fluorescent
dye seems more promising, but more
experience is needed. Nevertheless, image
analysis may well serve to assess objectively the
number of positive cells,'6 ' although it re-
mains a rather labourious and relatively expen-
sive procedure.
Recently, an interactive approach for immu-
noscoring has been developed based on
stereology,4 18-20 which is very quick, simple, and
reproducible. In a defined area of the lesion,
fields of vision systematically spread over the
whole area of interest are chosen, as illustrated
in fig 1. As the first field is chosen at random, all
fields are random, so this way of sampling is
called systematic at random. This can be done
manually, but is most efficiently done by means
of a software guided automatic scanning stage.
In these fields of vision, cells are selected using
a point grid, and the positivity of these cells is
scored. The principle here is to sample relatively
few cells from relatively many fields of vision, or
the "do more less well" principle.2' 22 The num-
ber of fields of vision and cells to be assessed
will vary from application to application and is
Figure 1 Schematic explanation of the suggested protocolfor interactive stereological
immunoscoring based on systematic random sampling.
802
Consensus on scoring for immunohistochemical staining
dependent on the desired accuracy. In practice,
200 cells sampled from 50-100 fields of vision
will allow a coefficient of variation < 5%.19 21
However, on occasion (for example, in case of
values very close to the decision threshold) one
may have to count more cells to reach an even
higher accuracy. In general, it is not necessary to
count 1000 cells as has been suggested.23 As
fields spread over the whole area of interest are
assessed (which copes best with clustering that
is often observed) and selection of cells is un-
biased, this approach leads to the highest
reproducibility.4 19 Good clinical correlations
with this method have been found in Barrett's
oesophagus,20 breast cancer,4 and lymphomas.'5
This approach is especially useful to assess
the percentage of positive cells irrespective of
the staining intensity, but obviously does not
overcome the problems involved in the subjec-
tive assessment of degree of positivity as previ-
ously mentioned.
Choice of cut off points
After having assessed the percentage of positive
cells, the question is obviously how to choose
the cut off value for decision making on "posi-
tivity". To this end, different approaches may
be followed. First, staining percentages may be
compared with biochemical findings. Second, a
cut off point may be tuned to molecular
biological results-for example, presence of
DNA amplification or the amount of mRNA.
Third, one may derive a cut off point from
clinical studies taking clinical end points such
as recurrence or survival, or response to a cer-
tain treatment. Preferably, such clinical cut off
points should be established in a learning set of
patients and confirmed in an independent
patient group. Also, cut off points should be
standardised from one study to another. This is
essential for semiquantitative scoring.
Reporting
Results of immunoquantitation should prefer-
ably not just be reported as positive or negative,
but the quantification method should be
provided as well as exact data from the quanti-
tation and the decision threshold. This can be
done by merely providing the data, but graphi-
cally presenting the data may be more illumi-
nating and easy to understand.
Summary of suggested protocol
In summary, when you are interested not just in
mere presence of antigen but the fraction of
positive cells is of interest irrespective of the
staining intensity, we suggest an interactive
stereological approach in a carefully defined part
of the lesion. This consists of a systematic
random sampling of fields of vision, preferen-
tially guided by an automatic scanning stage,
and assessment of positivity of cells in these
fields selected with a point grid. Technically
adequate slides are a prerequisite. An example of
a protocol for such an approach is presented
below:
0 define the relevant staining pattern (nuclear,
cytoplasmic or membrane) and consider
only this pattern
* define the area of the lesion to be assessed
(periphery v central parts), relevant tissue
parts (in situ v invasive), and cells of interest
* in this area, apply a systematic random sam-
pling approach for selection of a defined
number of fields of vision
* in the fields of vision, assess positivity of cells
selected with a point grid
* define the number of cells to be assessed,
using the principle that few cells should be
sampled from many fields of vision (for
example, 2-4 cells from 50-100 fields of
vision yielding a total of 200 counts)
* define cut off value
* define how the results should be reported.
Such methods are fast, simple and highly
reproducible. Application of such protocols
will yield more objective data on the distribu-
tion of antigens in different lesions, which will
be easier to compare from study to study, and
will speed the process towards clinically appli-
cable tests.
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